Market Closed -
OTC Markets
18:42:31 10/06/2024 BST
|
5-day change
|
1st Jan Change
|
0.000001
USD
|
0.00%
|
|
0.00%
|
0.00%
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Capitalization
1 |
12.01
|
18.06
|
20.57
|
18.79
|
2.48
|
3.605
|
Enterprise Value (EV)
2 |
11.88
|
17.47
|
20.52
|
18.93
|
2.841
|
4.039
|
P/E ratio
|
-2.76
x
|
-1.9
x
|
-1.81
x
|
-2.88
x
|
-11.5
x
|
-1.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-
|
-2,743,443
x
|
-3,233,280
x
|
-3,824,661
x
|
-83,119,296
x
|
-7,452,621
x
|
EV / FCF
|
-21.1
x
|
-4.51
x
|
-10.6
x
|
-175
x
|
-9.28
x
|
32.3
x
|
FCF Yield
|
-4.74%
|
-22.2%
|
-9.4%
|
-0.57%
|
-10.8%
|
3.09%
|
Price to Book
|
8.95
x
|
8.89
x
|
99.2
x
|
-8.45
x
|
-0.92
x
|
-0.81
x
|
Nbr of stocks (in thousands)
|
41,523
|
64,938
|
112,378
|
126,378
|
126,378
|
130,228
|
Reference price
3 |
0.2893
|
0.2780
|
0.1830
|
0.1487
|
0.0196
|
0.0277
|
Announcement Date
|
27/04/17
|
27/04/18
|
23/08/19
|
11/08/20
|
30/04/21
|
14/07/22
|
1USD in Million2CAD in Million3USD Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-6.369
|
-6.347
|
-4.949
|
-0.0342
|
-0.5419
|
EBIT
1 |
-2.384
|
-6.369
|
-6.347
|
-4.95
|
-0.0344
|
-0.5422
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-3.008
|
-8.494
|
-7.442
|
-5.137
|
-0.1734
|
-1.818
|
Net income
1 |
-3.008
|
-8.494
|
-7.442
|
-5.137
|
-0.1734
|
-1.818
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1046
|
-0.1463
|
-0.1012
|
-0.0516
|
-0.001710
|
-0.0179
|
Free Cash Flow
1 |
-0.5631
|
-3.873
|
-1.929
|
-0.1084
|
-0.306
|
0.125
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/04/17
|
27/04/18
|
23/08/19
|
11/08/20
|
30/04/21
|
14/07/22
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
-
|
-
|
-
|
0.14
|
0.36
|
0.43
|
Net Cash position
1 |
0.13
|
0.58
|
0.05
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.0287
x
|
-10.54
x
|
-0.8006
x
|
Free Cash Flow
1 |
-0.56
|
-3.87
|
-1.93
|
-0.11
|
-0.31
|
0.12
|
ROE (net income / shareholders' equity)
|
-684%
|
-504%
|
-815%
|
511%
|
7.06%
|
50.9%
|
ROA (Net income/ Total Assets)
|
-181%
|
-210%
|
-255%
|
-239%
|
-1.77%
|
-51.5%
|
Assets
1 |
1.663
|
4.053
|
2.913
|
2.152
|
9.793
|
3.532
|
Book Value Per Share
2 |
0.0300
|
0.0300
|
0
|
-0.0200
|
-0.0200
|
-0.0300
|
Cash Flow per Share
2 |
0
|
0.0100
|
0
|
0
|
0
|
0
|
Capex
|
-
|
0
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/04/17
|
27/04/18
|
23/08/19
|
11/08/20
|
30/04/21
|
14/07/22
|
|
1st Jan change
|
Capi.
|
---|
| -40.31% | 8.15B | | +8.65% | 3.6B | | -0.25% | 2.27B | | -24.56% | 1.9B | | -18.21% | 1.72B | | +5.95% | 922M | | +16.75% | 731M | | -10.48% | 679M | | -0.60% | 288M |
Bio Diagnostics & Testing
|